Cellular immunotherapy after allogeneic stem cell transplantation in hematologic malignancies
Authors:
- Hans-Jochem KolbHKHans-Jochem Kolb
- Belinda SimoesBSBelinda Simoes
- Christoph SchmidCSChristoph Schmid
- 1 March 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 16 (2) , 167-173
Abstract
The chimeric state after allogeneic stem cell transplantation provides an ideal platform for adoptive immunotherapy of hematologic malignancies using donor-derived cells. The present review aims to summarize recent results of the transfusion of donor-derived cells with regard to the diseases treated, the cells used for treatment, and the origin of these cells. The transfusion of donor lymphocytes has been studied widely, not only in patients with recurrent disease, persistent disease, and mixed chimerism but also in a variety of hematologic malignancies. Donors of lymphocytes and hematopoietic stem cells have been HLA-identical siblings, HLA-matched unrelated donors, and HLA-different haploidentical family members. A variety of cells have been used for adoptive immunotherapy, including plain lymphocytes, selected T cells, T cell lines, and T cell clones. The possible therapies have been expanded by natural killer cells and natural killer T cells as well as antibodies directing the effector cells toward the malignancy. Adoptive immunotherapy in chimeras has become not only a routine form of treatment of recurrent hematologic malignancy but also a prophylactic measure in high-risk leukemia and lymphoma.Keywords
This publication has 94 references indexed in Scilit:
- Molecular monitoring of responses to DLI and DLI + IFN treatment of post-SCT relapses in patients with CMLLeukemia Research, 2003
- Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusionsBone Marrow Transplantation, 2003
- Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemiaBlood, 2002
- Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell doseBlood, 2002
- Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantationBlood, 2002
- Long-term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantationTransplantation and Cellular Therapy, 2001
- Interferon alpha in combination with GM-CSF induces the differentiation of leukaemic antigen-presenting cells that have the capacity to stimulate a specific anti-leukaemic cytotoxic T-cell response from patients with chronic myeloid leukaemiaBritish Journal of Haematology, 2000
- T cells recognizing leukemic CD34 + progenitor cells mediate the antileukemic effect of donor lymphocyte infusions for relapsed chronic myeloid leukemia after allogeneic stem cell transplantationProceedings of the National Academy of Sciences, 1998
- Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.Journal of Clinical Oncology, 1997
- Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patientsBlood, 1990